Pushko Peter, Tumpey Terrence M, Bu Fang, Knell John, Robinson Robin, Smith Gale
Novavax, Inc., Vaccine Technologies, 1 Taft Court, Rockville, MD 20850, USA.
Vaccine. 2005 Dec 30;23(50):5751-9. doi: 10.1016/j.vaccine.2005.07.098. Epub 2005 Aug 15.
Avian influenza viruses represent a growing threat for an influenza pandemic. To develop recombinant vaccine for avian influenza of the H9N2 subtype, we expressed in insect cells virus-like particles (VLPs) consisting of three structural proteins of influenza A/Hong Kong/1073/99 (H9N2) virus. Upon infection of Sf9 cells with recombinant baculoviruses, the hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins were co-expressed in the infected cells, self-assembled, and released into the culture medium as VLPs of 80-120nm in diameter. VLPs exhibited functional characteristics of influenza virus including hemagglutination and neuraminidase activities. In BALB/c mice, VLPs elicited serum antibodies specific for influenza A/Hong Kong/1073/99 (H9N2) virus and inhibited replication of the influenza virus after challenge. Thus, VLPs represent a potential strategy for the development of human vaccines against avian influenza H9N2 viruses.
禽流感病毒对流感大流行构成了日益严重的威胁。为研发H9N2亚型禽流感重组疫苗,我们在昆虫细胞中表达了由甲型流感病毒A/香港/1073/99(H9N2)的三种结构蛋白组成的病毒样颗粒(VLP)。用重组杆状病毒感染Sf9细胞后,血凝素(HA)、神经氨酸酶(NA)和基质(M1)蛋白在感染细胞中共同表达、自组装,并以直径80 - 120nm的VLP形式释放到培养基中。VLP表现出流感病毒的功能特性,包括血凝和神经氨酸酶活性。在BALB/c小鼠中,VLP引发了针对甲型流感病毒A/香港/1073/99(H9N2)的血清抗体,并在攻毒后抑制了流感病毒的复制。因此,VLP是开发针对H9N2禽流感病毒的人类疫苗的一种潜在策略。